A new study published in the Journal of Toxicology and Environmental Health has linked the increase in female infertility with the ‘dangerous’ HPV vaccine.
According to researchers, the lowered probability of pregnancy in the USA in women aged 25-29 is directly connected to the introduction of the human papilloma vaccine.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
Ageofautism.com reports: Birth rates in the United States have recently fallen. Birth rates per 1000 females aged 25–29 fell from 118 in 2007 to 105 in 2015.
One factor may involve the vaccination against the human papillomavirus (HPV). Shortly after the vaccine was licensed, several reports of recipients experiencing primary ovarian failure emerged.
This study analyzed information gathered in National Health and Nutrition Examination Survey, which represented 8 million 25-to-29-year-old women residing in the United States between 2007 and 2014.
Approximately 60% of women who did not receive the HPV vaccine had been pregnant at least once, whereas only 35% of women who were exposed to the vaccine had conceived.
For married women, 75% who did not receive the shot were found to conceive, while only 50% who received the vaccine had ever been pregnant.
Using logistic regression to analyze the data, the probability of having been pregnant was estimated for females who received an HPV vaccine compared with females who did not receive the shot.
Results suggest that females who received the HPV shot were less likely to have ever been pregnant than women in the same age group who did not receive the shot.
If 100% of females in this study had received the HPV vaccine, data suggest the number of women having ever conceived would have fallen by 2 million. Further study into the influence of HPV vaccine on fertility is thus warranted.
Gayle DeLong, PhD, is an Associate Professor of Economics and Finance in the Bert W. Wasserman Department of Economics and Finance at Baruch’s Zicklin School of Business.
Dr. DeLong has published in leading journals, including Journal of Finance, Journal of Financial Economics, Journal of International Money and Finance, Financial Management, and Journal of Financial Research.
Research interests include bank acquisitions, regulatory capture, and conflicts of interest. DeLong, the 2013 recipient of the Abraham J. Briloff Prize in Ethics as well as the 2010 recipient of the Zicklin School of Business Teaching Excellence Award, holds a PhD in finance and international business from New York University.
Sean Adl-Tabatabai